A Novel PTP1b Inhibitor Vanadium-Flavone Complex: Synthesis and Pharmacodynamic Evaluation in Streptozotocin-Induced Diabetic Mice
Liying Duan,Junwei Ye,Wenlong Sun,Shaoning Wang,Wei-tao Gong,Yuesheng Dong,Guiling Ning
DOI: https://doi.org/10.1007/s00044-017-1895-9
2017-01-01
Medicinal Chemistry Research
Abstract:Protein tyrosine phosphatase 1b is a negative regulator of insulin action and is emerging as a potential drug target for type 2 diabetes mellitus. A novel protein tyrosine phosphatase 1b inhibitor vanadium-flavone complex, bis (5,6,7-trihydroxyflavone)-oxovanadium, was synthesized and characterized by mass spectrometer, inductively coupled plasma, infrared, ultraviolet, electron paramagnetic resonance, X-ray photoelectron spectroscopy and thermal gravity analysis. Bis (5,6,7-trihydroxyflavone)-oxovanadium showed good anti-diabetic effect in streptozocin -induced diabetic mice without gastrointestinal stimulation and induction of hypoglycemia in normoglycemic mice. In vitro, the protein tyrosine phosphatase 1b inhibition activity of bis (5,6,7-trihydroxyflavone)-oxovanadium was enhanced after storage, during which bis (5,6,7-trihydroxyflavone)-oxovanadium could be decomposed gradually and the concentration of VO 2+ would gradually increase. In vivo, baicalein not only transports VO 2+ to the target organ, but also improves the morphology and function of pancreatic islets via its anti-inflammation activity. Thus bis (5,6,7-trihydroxyflavone)-oxovanadium is a promising potential drug for the treatment of type 2 diabetes mellitus.